Themis Medicare Limited

THEMISMED

INE083B01024

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:46 06/03/2026 pm IST			5-day change	1st Jan Change
79.05 ^INR	-0.29%		-8.40%	-21.46%

25/02	Themis Medicare Limited announced that it expects to receive INR 114.619127 million in funding	CI
14/02	Themis Medicare Limited Announces Executive Changes	CI

Themis Medicare Limited Reports Earnings Results for the First Quarter Ended June 30, 2024

Published on 07/26/2024 at 07:26 pm IST

S&P Capital IQ

THEMIS MEDICARE LIMITED

-0.29%

Themis Medicare Limited reported earnings results for the first quarter ended June 30, 2024. For the first quarter, the company reported sales was INR 1,229.94 million compared to INR 966.48 million a year ago. Revenue was INR 1,239.52 million compared to INR 973.01 million a year ago.

Net income was INR 246.85 million compared to INR 181.93 million a year ago. Basic earnings per share from continuing operations was INR 2.68 compared to INR 1.98 a year ago. Diluted earnings per share from continuing operations was INR 2.68 compared to INR 1.97 a year ago.

Latest news about Themis Medicare Limited

25/02	Themis Medicare Limited announced that it expects to receive INR 114.619127 million in funding	CI
14/02	Themis Medicare Limited Announces Executive Changes	CI
13/02	Themis Medicare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025	CI
13/11	Themis Medicare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025	CI
10/11	Themis Medicare Limited Announces Cessation of Manjul Sandhu as Independent Woman Director, Effective November 10, 2025	CI
02/25/02	Themis Medicare Limited Reports Earnings Results for the First Quarter Ended June 30, 2025	CI
01/25/01	Themis Medicare Limited Approves Appointment of Viraj Save as Executive President - Sales & Marketing, Effective 1st August, 2025	CI
13/25/13	Themis Medicare Limited cancelled the acquisition of remaining 76.8% stake in Gujarat Themis Biosyn Limited.	CI
21/25/21	Themis Medicare Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025	CI
20/25/20	Themis Medicare Limited Recommends Final Dividend for the Financial Year Ended 31St March 2025	CI
20/25/20	Themis Medicare Limited Enters into Memorandum of Understanding with Gedeon Richter Plc., Hungary	CI
14/25/14	Themis Medicare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024	CI
19/24/19	Themis Medicare Limited Receives the Tax Demand from the Income Tax Department, Vapi, Gujarat, for the Assessment Year 2018-19	CI
18/24/18	Themis Medicare Limited agreed to acquire remaining 76.8% stake in Gujarat Themis Biosyn Limited for INR 26.9 billion.	CI
25/24/25	Themis Medicare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2024	CI

Chart Themis Medicare Limited

Duration

Period

THEMISMED: Dynamic Chart

Company Profile

Themis Medicare Limited is a research-based pharmaceutical company, which is engaged in the manufacturing of pharmaceutical products, especially in formulation and active pharmaceutical ingredients (API) activity. The Company operates through one segment: Pharmaceuticals. The Company manufactures therapeutic pharma products, differential healthcare products, and APIs based in India. The Company specializes in manufacturing a range of products for application areas like pain management, critical care and anti-infectives. Its analgesic and anti-inflammatory products include Aquadol Tpm Gel, Etojet 90 10'S, Etojet 120 10'S, Etojet Mr Tablets 10'S, Etojet XP Gel, Themidol-P Tab 10's, Dhoom, Aquadol inj, Dyloaqua inj, Joydol -P, Joydol -SP, Joydol -TH, and Nimujet Gel. Its Analgesics products include Anemol, Tazowin, Themidol, Themidol. Its Anesthesia products include Bupicaine 0.25%, Ketmin 2 Vial, Ketmin 5, Ropicaine 2, Themicaine 2%, and more.

Employees

1,702

Sector

Pharmaceuticals

Calendar

30/05 - Earnings release - Annual 2026

More about the company